VitaSpring Biomedical Co. Ltd. (VSBC) stock
VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $6.58MP/E –Yield –
VitaSpring Biomedical revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
VitaSpring Biomedical's revenue for the twelve months ending Jul 31, 2026 was $0. For fiscal 2026 it was $0. The highest annual figure on record is $5.61M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $0 | – |
| FY2025 | Jan 31, 2025 | $0 | – |
| FY2024 | Jan 31, 2024 | $0 | – |
| FY2023 | Jan 31, 2023 | $0 | -100.0% |
| FY2022 | Jan 31, 2022 | $5.61M | +2161.6% |
| FY2021 | Jan 31, 2021 | $248.20K | +1539.4% |
| FY2020 | Jan 31, 2020 | $15.14K | -11.9% |
| FY2019 | Jan 31, 2019 | $17.18K | +5.9% |
| FY2018 | Jan 31, 2018 | $16.23K | – |
| FY2017 | Jan 31, 2017 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ2 2026 | Jul 31, 2026 | $0 | – |
| Q1 FY2027CQ1 2026 | Apr 30, 2026 | $0 | – |
| Q4 FY2026CQ4 2025 | Jan 31, 2026 | $0 | – |
| Q3 FY2026CQ3 2025 | Oct 31, 2025 | $0 | – |
| Q2 FY2026CQ2 2025 | Jul 31, 2025 | $0 | – |
| Q1 FY2026CQ1 2025 | Apr 30, 2025 | $0 | – |
| Q4 FY2025CQ4 2024 | Jan 31, 2025 | $0 | – |
| Q3 FY2025CQ3 2024 | Oct 31, 2024 | $0 | – |
| Q2 FY2025CQ2 2024 | Jul 31, 2024 | $0 | – |
| Q1 FY2025CQ1 2024 | Apr 30, 2024 | $0 | – |
| Q4 FY2024CQ4 2023 | Jan 31, 2024 | $0 | – |
| Q3 FY2024CQ3 2023 | Oct 31, 2023 | $0 | – |
| Q2 FY2024CQ2 2023 | Jul 31, 2023 | $0 | -100.0% |
| Q1 FY2024CQ1 2023 | Apr 30, 2023 | $0 | -100.0% |
| Q3 FY2023CQ3 2022 | Oct 31, 2022 | $0 | -100.0% |
| Q2 FY2023CQ2 2022 | Jul 31, 2022 | $0 | -100.0% |
| Q1 FY2023CQ1 2022 | Apr 30, 2022 | $1.49M | +179.1% |
| Q4 FY2022CQ4 2021 | Jan 31, 2022 | $3.49M | +1305.7% |
| Q3 FY2022CQ3 2021 | Oct 31, 2021 | $200.00K | – |
| Q2 FY2022CQ2 2021 | Jul 31, 2021 | $1.39M | – |
| Q1 FY2022CQ1 2021 | Apr 30, 2021 | $533.80K | – |
| Q4 FY2021CQ4 2020 | Jan 31, 2021 | $248.20K | +6183.5% |
| Q3 FY2021CQ3 2020 | Oct 31, 2020 | $0 | – |
| Q2 FY2021CQ2 2020 | Jul 31, 2020 | $0 | – |
| Q1 FY2021CQ1 2020 | Apr 30, 2020 | $0 | -100.0% |
| Q4 FY2020CQ4 2019 | Jan 31, 2020 | $3.95K | +48.8% |
| Q3 FY2020CQ3 2019 | Oct 31, 2019 | $0 | -100.0% |
| Q2 FY2020CQ2 2019 | Jul 31, 2019 | $0 | -100.0% |
| Q1 FY2020CQ1 2019 | Apr 30, 2019 | $7.22K | -42.0% |
| Q4 FY2019CQ4 2018 | Jan 31, 2019 | $2.66K | +60.9% |
| Q3 FY2019CQ3 2018 | Oct 31, 2018 | $75 | -97.8% |
| Q2 FY2019CQ2 2018 | Jul 31, 2018 | $2.00K | -60.0% |
| Q1 FY2019CQ1 2018 | Apr 30, 2018 | $12.45K | +103.4% |
| Q4 FY2018CQ4 2017 | Jan 31, 2018 | $1.65K | – |
| Q3 FY2018CQ3 2017 | Oct 31, 2017 | $3.46K | – |
| Q2 FY2018CQ2 2017 | Jul 31, 2017 | $5.00K | – |
| Q1 FY2018CQ1 2017 | Apr 30, 2017 | $6.12K | – |
See a number that looks wrong?